Literature DB >> 26912424

A Microdosimetric Analysis of Absorbed Dose to Tumor as a Function of Number of Microspheres per Unit Volume in 90Y Radioembolization.

Alexander S Pasciak1, Austin C Bourgeois2, Yong C Bradley3.   

Abstract

UNLABELLED: Differences in maximum tolerable absorbed dose to normal liver between (90)Y radioembolization and external-beam radiation therapy have been explained by citing differences in absorbed-dose heterogeneity at the microscopic level. We investigated microscopic absorbed-dose heterogeneity in radioembolization as a function of the number of microspheres per unit volume in tumor. The goal was to determine what effect the number of microspheres may have, if any, on tumor control in (90)Y radioembolization.
METHODS: (90)Y PET/CT data were combined with microscopic probability-density functions describing microsphere clustering to provide realistic simulation using Monte Carlo modeling on both a macroscopic and a microscopic level. A complete microdosimetric analysis using 100-μm voxels was performed on the basis of (90)Y PET/CT data from 19 tumors treated using radioembolization. Simulations were performed with average tumor microsphere-number densities from 200 to 70,000 spheres/mL. Monte Carlo simulations of each tumor and number density were repeated 20 times to establish SE. A 2-way balanced ANOVA was used to determine whether differences in microsphere-number density affected common tumor-dose metrics.
RESULTS: Decreasing the microsphere-number density resulted in a decrease in D70, the minimum dose to 70% of the tumor. The slope of the dose-volume histogram also decreased with decreasing microsphere-number density in all tumors. Compared with a density of 50,000 spheres/mL, decreases in D70 were statistically significant below 20,000 spheres/mL. However, these differences are unlikely to have clinical significance until the density decreases to below 5,000 spheres/mL. Although D70 was decreased at a low microsphere-number density, one can compensate for decreases by an increase in the average tumor-absorbed dose, that is, by increasing the radioembolization treatment dose.
CONCLUSION: Differences in microsphere-number density may have an effect on microscopic tumor absorbed-dose inhomogeneity. These results begin to explain differences in treatment planning strategies between glass and resin radioembolization devices.
© 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  90Y; interventional oncology; radioembolization; yttrium-90

Mesh:

Substances:

Year:  2016        PMID: 26912424     DOI: 10.2967/jnumed.115.163444

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  12 in total

Review 1.  Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2017-05-02       Impact factor: 3.959

2.  Spatial density and tumor dosimetry are important in radiation segmentectomy with 90Y glass microspheres.

Authors:  Carlo Chiesa; Stefania Mazzaglia; Marco Maccauro
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-09       Impact factor: 10.057

Review 3.  Radioembolization for the Treatment of Hepatocellular Carcinoma: The Road to Personalized Dosimetry and Ablative Practice.

Authors:  Cynthia De la Garza-Ramos; Beau B Toskich
Journal:  Semin Intervent Radiol       Date:  2021-10-07       Impact factor: 1.780

4.  Feasibility of Combination Intra-arterial Yttrium-90 and Irinotecan Microspheres in the VX2 Rabbit Model.

Authors:  Andrew C Gordon; Sarah B White; Yihe Yang; Vanessa L Gates; Daniel Procissi; Kathleen R Harris; Zhuoli Zhang; Tianchu Lyu; Xiaoke Huang; Matthew R Dreher; Reed A Omary; Riad Salem; Robert J Lewandowski; Andrew C Larson
Journal:  Cardiovasc Intervent Radiol       Date:  2020-06-12       Impact factor: 2.740

5.  The number of microspheres in Y90 radioembolization directly affects normal tissue radiation exposure.

Authors:  Alexander S Pasciak; Godwin Abiola; Robert P Liddell; Nathan Crookston; Sepideh Besharati; Danielle Donahue; Richard E Thompson; Eric Frey; Robert A Anders; Matthew R Dreher; Clifford R Weiss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-18       Impact factor: 9.236

6.  Clinical and imaging-based prognostic factors in radioembolisation of liver metastases from colorectal cancer: a retrospective exploratory analysis.

Authors:  Kathy P Willowson; Aimee R Hayes; David L H Chan; Michael Tapner; Elizabeth J Bernard; Richard Maher; Nick Pavlakis; Stephen J Clarke; Dale L Bailey
Journal:  EJNMMI Res       Date:  2017-05-23       Impact factor: 3.138

7.  Radioembolization of Hepatocellular Carcinoma with Built-In Dosimetry: First in vivo Results with Uniformly-Sized, Biodegradable Microspheres Labeled with 188Re.

Authors:  José Carlos De La Vega; Pedro Luis Esquinas; Cristina Rodríguez-Rodríguez; Mehrdad Bokharaei; Igor Moskalev; David Liu; Katayoun Saatchi; Urs O Häfeli
Journal:  Theranostics       Date:  2019-01-25       Impact factor: 11.556

Review 8.  Microspheres Used in Liver Radioembolization: From Conception to Clinical Effects.

Authors:  Philippe d'Abadie; Michel Hesse; Amandine Louppe; Renaud Lhommel; Stephan Walrand; Francois Jamar
Journal:  Molecules       Date:  2021-06-29       Impact factor: 4.411

Review 9.  The physics of radioembolization.

Authors:  Remco Bastiaannet; S Cheenu Kappadath; Britt Kunnen; Arthur J A T Braat; Marnix G E H Lam; Hugo W A M de Jong
Journal:  EJNMMI Phys       Date:  2018-11-02

10.  Neutron-activated biodegradable samarium-153 acetylacetonate-poly-L-lactic acid microspheres for intraarterial radioembolization of hepatic tumors.

Authors:  Yin-How Wong; Hun-Yee Tan; Azahari Kasbollah; Basri Johan Jeet Abdullah; Rajendra Udyavara Acharya; Chai-Hong Yeong
Journal:  World J Exp Med       Date:  2020-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.